Abstract:The pro-drug pyrazinamide is hydrolyzed to pyrazinoic acid (POA) in its use for the treatment of tuberculosis. As a molecule with bactericidal activity, POA binds to the C-terminal S1 domain of ribosomal protein S1 from Mycobacterium tuberculosis ( Mt RpsA CTD _S1) to inhibit trans-translation. Trans-translation is a critical component of protein synthesis quality control, and is mediated by transfer-messenger RNA. Here, we have determined the solution structure of Mt RpsA CTD _S1(280–368), and analyzed its structural dynamics by NMR spectroscopy. The solution structure of Mt RpsA CTD _S1(280–368) mainly consists of five anti-parallel β strands, two α helices, and two 3 10 helices. Backbone dynamics reveals that the overall structure of Mt RpsA CTD _S1(280–368) is rigid, but segment L326–V333 undergoes large amplitude fluctuations on picosecond to nanosecond time scales. In addition, residues V321, H322, V331 and D335 with large R ex values exhibit significant chemical or conformational exchange on microsecond to millisecond time scale. Titration of the truncated Mt RpsA CTD _S1(280–368) with POA shows similar characteristics to titration of Mt RpsA CTD _S1(280–438) with POA. In addition, diverse length fragments of Mt RpsA CTD _S1 show various HN resonance signals, and we find that the interaction of Mt RpsA(369–481) with Mt RpsA CTD _S1(280–368) [ K d = (4.25 ± 0.15) mM] is responsible for the structural difference between Mt RpsA CTD _S1(280–368) and Mt RpsA CTD _S1. This work may shed light on the underlying molecular mechanism of Mt RpsA CTD recognizing and binding POA or mRNA, as well as the detailed mechanism of interactions between Mt RpsA CTD _S1(280–368) and the additional C-terminal Mt RpsA(369–481).

Crystal structure of a bioactive pactamycin analog bound to the 30S ribosomal subunit

Deciphering pactamycin biosynthesis and engineered production of new pactamycin analogues

Chemical Modification of Pactamycin Leads to New Compounds with Retained Antimicrobial Activity and Reduced Toxicity

Distant Ribose 2'-O-Methylation of 23S rRNA Helix 69 Pre-Orders the Capreomycin Drug Binding Pocket at the Ribosome Subunit Interface

Discovery and evaluation of new compounds targeting ribosomal protein S1 in antibiotic-resistant Mycobacterium Tuberculosis.

Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3

Solution structure and backbone dynamics for S1 domain of ribosomal protein S1 from Mycobacterium tuberculosis

Structural Study of a New MbtI-Inhibitor Complex: Towards an Optimized Model for Structure-Based Drug Discovery

Synthesis and antibacterial action of 3',6'-disubstituted spectinomycins

Structural basis for contrasting activities of ribosome binding thiazole antibiotics.

Cryo-EM Structure of Mycobacterium Tuberculosis 50S Ribosomal Subunit Bound with Clarithromycin Reveals Dynamic and Specific Interactions with Macrolides

Establishing the Comprehensive Structure−Activity Relationship of the Natural Antibiotic Kibdelomycin/Amycolamicin

Design of Coibamide A Mimetics with Improved Cellular Bioactivity

Crystal Structure of 7,8-Dihydropteroate Synthase from Bacillus anthracisMechanism and Novel Inhibitor Design

An antibiotic preorganized for ribosomal binding overcomes antimicrobial resistance

Structural basis for the context-specific action of the classic peptidyl transferase inhibitor chloramphenicol

Molecular structure of antitumor drug steffimycin and modelling of its binding to DNA

Lead Compounds and Key Residues of Ribosomal Protein S1 in Drug-Resistant Mycobacterium Tuberculosis.

Design, Crystal Structure and Atomic Force Microscopy Study of Thioether Ligated D,l-Cyclic Antimicrobial Peptides Against Multidrug Resistant Pseudomonas Aeruginosa

MDN-0170, a New Napyradiomycin from Streptomyces sp. Strain CA-271078

Structural insights into the biological activity of a thioxopyrimidine derivative